STOCK TITAN

Citadel discloses 3.5% DBV Technologies stake (NASDAQ: DBVT)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

DBV Technologies S.A. received an updated ownership report from a group of Citadel-affiliated entities and Kenneth Griffin on its ordinary shares. The filing states that Mr. Griffin may be deemed to beneficially own 8,146,510 shares, representing 3.5% of the company’s outstanding shares as of December 31, 2025.

Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 7,413,959 shares, or 3.1% of the class, while various Citadel Securities entities report smaller positions. All reported voting and dispositive powers are shared rather than sole. The reporting group certifies the holdings are not intended to change or influence control of DBV Technologies.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 235,670,864 Shares outstanding as of December 31, 2025 (based on information obtained from the issuer's website on January 12, 2026).


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:02/17/2026
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:02/17/2026

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

FAQ

What stake in DBV Technologies (DBVT) does Kenneth Griffin report?

Kenneth Griffin may be deemed to beneficially own 8,146,510 DBV Technologies shares, equal to 3.5% of the outstanding shares as of December 31, 2025. This ownership is reported with shared voting and dispositive power, not sole control.

How many DBV Technologies shares are reported by Citadel Advisors entities?

Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 7,413,959 DBV Technologies shares. This position represents 3.1% of the company’s outstanding ordinary shares, based on 235,670,864 shares outstanding as of December 31, 2025.

What percentage of DBV Technologies does Citadel Securities report owning?

Citadel Securities LLC may be deemed to beneficially own 47,240 DBV Technologies shares, which the filing states as 0.0% of the shares outstanding. Related Citadel Securities Group LP and Citadel Securities GP LLC each report 732,551 shares, or 0.3% of the class.

Does the Citadel group seek control of DBV Technologies (DBVT)?

The reporting persons certify their DBV Technologies holdings were not acquired and are not held for changing or influencing control of the issuer. They also state the holdings are not in connection with any transaction having that control-related purpose or effect.

On what share count is the DBV Technologies ownership percentage based?

The reported ownership percentages are calculated using 235,670,864 DBV Technologies ordinary shares outstanding as of December 31, 2025. This outstanding share figure was obtained from the issuer’s website on January 12, 2026, according to the filing.

Who are the reporting persons in this DBV Technologies Schedule 13G/A?

The filing is jointly submitted by Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC and Kenneth Griffin. They report indirect holdings through various managed and affiliated entities.
Dbv Technologies S A

NASDAQ:DBVT

DBVT Rankings

DBVT Latest News

DBVT Latest SEC Filings

DBVT Stock Data

1.16B
50.80M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
France
CHATILLON